Result of AGM

RNS Number : 2963J

Epistem Holdings plc

16 December 2015

 

RNS Press Release

For release: 16 December 2015

Result of Annual General Meeting

Epistem Holdings Plc (LSE: EHP), the personalised medicine and biotechnology company, announces today that all resolutions were duly passed at its Annual General Meeting, held today in London.

For further details please contact:

Epistem Holdings Plc

Dr Ian Gilham: Chairman                                                                                       [phone]

John Rylands: Finance Director

Peel Hunt LLP

James Steel                                                                                                              [phone]

Tom Burt

Oliver Jackson

Consilium Strategic Communications

Chris Gardner / Laura Thornton                                                                          [phone]

[e-mail] 

Notes to Editors

Epistem is a personalised medicine and biotechnology company developing innovative diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem's Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the Indian sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com

 

END

 

 

RAGFFSFLMFISEFE